Patents by Inventor Yue-Sheng Li

Yue-Sheng Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGF21 Mutants and Uses Thereof
    Publication number: 20190023757
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 1, 2018
    Publication date: January 24, 2019
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Methods of treating of diabetes and obesity using FGF21 mutants
    Patent number: 10011642
    Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 3, 2018
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • CARRIER IMMUNOGLOBULINS
    Publication number: 20170190793
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 6, 2017
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
  • Stabilized Receptor Polypeptides and Uses Thereof
    Publication number: 20170183391
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 29, 2017
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • Carrier immunoglobulins
    Patent number: 9562108
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 7, 2017
    Assignee: AMGEN INC.
    Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
  • Carrier immunoglobulins
    Patent number: 9562107
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 7, 2017
    Assignee: AMGEN INC.
    Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, George Doellgast, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
  • FGF21 mutants comprising a mutation at position 98, 171 and/or 180
    Patent number: 9493530
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 15, 2016
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20160244497
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: January 27, 2016
    Publication date: August 25, 2016
    Inventors: Kenneth W. WALKER, Colin V. Gegg, JR., Randy I. Hecht, Edward J. Belouski, Yue-Sheng Li, Mark L. Michaels, Jing Xu, Murielle Marie Ellison
  • FGF MUTANTS AND USES THEREOF
    Publication number: 20160168223
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 16, 2016
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Stabilized Receptor Polypeptides and Uses Thereof
    Publication number: 20160137718
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: January 22, 2016
    Publication date: May 19, 2016
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • FGF-21 mutants comprising polyethylene glycol and uses thereof
    Patent number: 9279013
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides comprising extended in vivos half-lives, pharmaceutical compositions comprising FGF21 mutant polypeptides having extended in vivos half lives, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: March 8, 2016
    Assignee: Amgen Inc.
    Inventors: Kenneth W. Walker, Colin V. Gegg, Jr., Randy I. Hecht, Edward J. Belouski, Yue-Sheng Li, Mark L. Michaels, Jing Xu, Murielle M. Ellison
  • FGF mutants with reduced proteolysis and aggregation
    Patent number: 9273106
    Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 1, 2016
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Stabilized receptor polypeptides and uses thereof
    Patent number: 9273114
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: March 1, 2016
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas C. Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • CARRIER IMMUNOGLOBULINS
    Publication number: 20150044236
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: May 22, 2014
    Publication date: February 12, 2015
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
  • CARRIER IMMUNOGLOBULINS
    Publication number: 20150044235
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: May 22, 2014
    Publication date: February 12, 2015
    Applicant: Amgen Inc.
    Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
  • Human anti-IFN-? neutralizing antibodies as selective IFN-? pathway inhibitors
    Patent number: 8906371
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: December 9, 2014
    Assignees: Amgen Inc., E.R. Squibb & Sons, L.L.C.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20140323396
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: January 29, 2014
    Publication date: October 30, 2014
    Applicant: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 polypeptides comprising two or more mutations and uses thereof
    Patent number: 8835385
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: September 16, 2014
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20140243503
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: December 19, 2013
    Publication date: August 28, 2014
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eav Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF 21 polypeptides comprising two or more mutations and uses thereof
    Patent number: 8795985
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: August 5, 2014
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu